Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival

Autor: Ken Masubuchi, Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda, Hiroyuki Minemura, Yoshiaki Nagai, Yutaka Yamada, Takayuki Kishikawa, Yukihiro Umeda, Ayako Shiono, Hiroki Takechi, Jun Shiihara, Kyoichi Kaira, Kenya Kanazawa, Hirokazu Taniguchi, Takayuki Kaburagi, Hiroshi Kagamu, Koichi Minato
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Thoracic Cancer, Vol 13, Iss 19, Pp 2776-2785 (2022)
Druh dokumentu: article
ISSN: 1759-7714
1759-7706
DOI: 10.1111/1759-7714.14621
Popis: Abstract Background The effect of first‐line chemotherapy on overall survival (OS) may be significantly influenced by subsequent therapy for patients with extensive disease small cell lung cancer (ED‐SCLC). Therefore, we evaluated the relationship between progression‐free survival (PFS), post‐progression survival (PPS), and OS of ED‐SCLC patients treated with atezolizumab plus carboplatin and etoposide as first‐line therapy. Methods We analyzed the data of 57 patients with relapsed ED‐SCLC treated with atezolizumab plus carboplatin and etoposide (AteCE) as first‐line chemotherapy between August 2019 and September 2020. The respective correlations between PFS‐OS and PPS‐OS following first‐line AteCE treatment were examined at the individual patient level. Results Spearman's rank correlation analysis and linear regression analysis showed that PPS strongly correlated with OS (r = 0.93, p
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje